Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Umbralisib Hits Primary Endpoint in Follicular Lymphoma Subgroup of Pivotal Study

October 29th 2019

Umbralisib (TGR-1202) met the primary endpoint of overall response rate in the follicular lymphoma cohort of the pivotal phase IIb UNITY-NHL trial, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.

Iomab-B Leads to High Bone Marrow Transplant Rate in Relapsed/Refractory AML

October 29th 2019

Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.

Gilteritinib Approved in Europe for Relapsed/Refractory FLT3+ AML

October 25th 2019

The European Commission has approved gilteritinib as a single agent for the treatment of relapsed/refractory patients with FLT3-mutant acute myeloid leukemia.

Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria

October 24th 2019

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Dr. Perl on Challenges of Implementing Immunotherapy in AML

October 23rd 2019

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Dr. Schiller on the Heterogeneity of AML

October 19th 2019

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

FDA Label Update Supports Earlier Use of Romiplostim for ITP

October 18th 2019

The FDA has approved a supplemental Biologics License Application for romiplostim, updating its label to include data demonstrating sustained platelet responses in adults with immune thrombocytopenia. Romiplostim is approved for the treatment of adult patients with newly diagnosed or persistent who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis

October 17th 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Dr. Schiller on Venetoclax and Glasdegib in AML

October 17th 2019

Gary J. Schiller, MD, discusses the benefits and challenges of using venetoclax and glasdegib in patients with relapsed/refractory acute myeloid leukemia.

Polatuzumab Vedotin Offers a New Option for Refractory DLBCL

October 17th 2019

Jeff Sharman, MD, discusses the current approval and potential future roles for polatuzumab vedotin-piiq (Polivy) in diffuse large B-cell lymphoma.

Ruxolitinib Hits Primary Endpoint in Phase III Acute GVHD Trial

October 17th 2019

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

Breaking Down Developments in Benign Hematologic Malignancies

October 16th 2019

Daria V. Babushok, MD, PhD, provides insight into the latest developments in the treatment of patients with benign hematologic malignancies.

Measuring MRD Imperative to Guide ALL Treatment Decisions

October 16th 2019

Noelle Frey, MD, MS, highlights various therapies available to patients with acute lymphocytic leukemia and the importance of measuring minimal residual disease.

Investigators Aim at B-Cell Malignancies Using Targeted Radiopharmaceutical

October 16th 2019

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

Novel Agents, Combo Regimens Poised to Dominate AML Treatment

October 15th 2019

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Lymphoma Advances Include Pivotal Trials, Novel Agents, and Effective Combos

October 14th 2019

Sunita Nasta, MD, discusses exciting updates in follicular lymphoma, diffuse large B-cell lymphoma, and T-cell lymphoma and the impact they will have on the upfront and relapsed/refractory paradigms.

Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment

October 12th 2019

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Hematologic Malignancy Research Gains Momentum at GW Cancer Center

October 11th 2019

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Role of MRD Still Evolving Across Hematologic Cancers

October 10th 2019

Imad Tabbara, MD, discusses the role of minimal residual disease testing in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, as well as emerging regimens in all 3 malignancies that are changing standards of care.